8 completed, 1 terminated, 1 withdrawn. 7 Phase 2, 3 Phase 1, 2 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 6, Withdrawn 1 |
| Phase 1 | 3 | Completed 3 |
| Not applicable | 2 | Completed 1, Terminated 1 |
| Phase 3 | 1 | Completed 1 |
Follow Extensive Stage Small Cell Lung Carcinoma: new trials by email Literature Review of Extensive Stage Small Cell Lung Carcinoma trials Research Report on Extensive Stage Small Cell Lung Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ALCMI-005: Pembrolizumab and Epacadostat in Treating Patients With Extensive Stage Small Cell Lung Cancer Pembrolizumab, Epacadostat, Laboratory Biomarker Analysis - Extensive Stage Small Cell Lung Carcinoma | Phase 2 | Withdrawn | City of Hope Medical Center | 2018-10-01 | 2026-05-29 | |
| Tumor-Treating Fields Therapy in Preventing Brain Tumors in Participants With Extensive-Stage Small Cell Lung Cancer Tumor Treating Fields (TTF) Therapy, NovoTTF-200A Device, Quality-of-Life Assessment - Extensive Stage Small Cell Lung Carcinoma | Not applicable | Terminated | Vanderbilt-Ingram Cancer Center | 2 | 2018-09-05 | 2020-08-04 |
| Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer Best Practice, Laboratory Biomarker Analysis, Supportive Care - Acute Myeloid Leukemia, Brain Glioblastoma | Not applicable | Completed | Stanford University | 128 | 2017-08-08 | 2025-01-24 |
| Whole-Brain Radiation Therapy With or Without Hippocampal Avoidance in Limited Stage or Extensive Stage Small Cell Lung Cancer Three-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy - Extensive Stage Small Cell Lung Carcinoma, Limited Stage Small Cell Lung Carcinoma | Phase 2 / Phase 3 | Completed | NRG Oncology | 418 | 2015-12-22 | 2026-07-10 |
| Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer Carboplatin, Cisplatin, Etoposide - Extensive Stage Small Cell Lung Carcinoma, Limited Stage Small Cell Lung Carcinoma | Phase 1 | Completed | M.D. Anderson Cancer Center | 83 | 2015-07-22 | 2026-03-10 |
| MK-3475 as Maintenance Therapy in Extensive Stage SCLC Pembrolizumab, Laboratory Biomarker Analysis - Extensive Stage Small Cell Lung Carcinoma | Phase 2 | Completed | Barbara Ann Karmanos Cancer Institute | 45 | 2015-02-01 | 2022-10-14 |
| Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer Auranofin, Sirolimus, Laboratory Biomarker Analysis - Extensive Stage Small Cell Lung Carcinoma, Lung Adenocarcinoma | Phase 1 / Phase 2 | Completed | Mayo Clinic | 29 | 2014-05-14 | 2025-09-05 |
| Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer Cisplatin, Etoposide, Veliparib - Extensive Stage Small Cell Lung Carcinoma, Large Cell Lung Carcinoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 156 | 2012-09-28 | 2026-06-24 |
| A Study of LY2510924 in Participants With Extensive-Stage Small Cell Lung Carcinoma LY2510924, Carboplatin, Etoposide - Extensive Stage Small Cell Lung Carcinoma | Phase 2 | Completed | Eli Lilly and Company | 90 | 2011-09-01 | 2019-07-23 |
| A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage Cisplatin, Cixutumumab, Etoposide - Extensive Stage Small Cell Lung Carcinoma, Recurrent Small Cell Lung Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 168 | 2009-07-16 | 2026-06-24 |
Carcinoma, Non-Small-Cell Lung (3) · Small Cell Lung Carcinoma (3) · Adenocarcinoma of Lung (1) · Bone Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Neuroendocrine (1) · Carcinoma, Renal Cell (1) · Carcinoma, Small Cell (1) · Colonic Neoplasms (1) · Disease Progression (1) · Esophageal Neoplasms (1) · Leukemia, Myeloid, Acute (1) · Melanoma (1) · Myelodysplastic Syndromes (1) · Neoplasm Metastasis (1)
Neoplasms (5) · Bronchial Neoplasms (4) · Carcinoma, Bronchogenic (4) · Lung Diseases (4) · Lung Neoplasms (4) · Neoplasms by Histologic Type (4) · Neoplasms by Site (4) · Respiratory Tract Diseases (4) · Respiratory Tract Neoplasms (4) · Thoracic Neoplasms (4) · Adenocarcinoma (3) · Carcinoma (3) · Neoplasms, Germ Cell and Embryonal (3) · Neoplasms, Glandular and Epithelial (3) · Neoplasms, Nerve Tissue (3)
Etoposide (4) · Cisplatin (3) · Platinum (3) · pembrolizumab (3) · 1,2-diaminocyclohexaneplatinum II citrate (2) · Carboplatin (2) · Auranofin (1) · HhAntag691 (1) · Immunoglobulin G (1) · LY2510924 (1) · Palliative Care (1) · Podophyllotoxin (1) · Practice Guidelines as Topic (1) · Radiation (1) · Radiotherapy (1)
National Cancer Institute (NCI) (2) · Barbara Ann Karmanos Cancer Institute (1) · City of Hope Medical Center (1) · Eli Lilly and Company (1) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1) · NRG Oncology (1) · Stanford University (1) · Vanderbilt-Ingram Cancer Center (1)
United States (10) · Canada (1)
Albert Attia, MD (1) · Ammar Sukari (1) · Chandra Belani (1) · Jacob Sands, MD (1) · James Welsh (1) · Manali Patel (1) · Ravi Salgia, MD (1) · Taofeek Owonikoko (1) · Vinai Gondi (1) · Yanyan Lou, M.D., Ph.D. (1)
PMID 28236984, PMID 30523756, PMID 31605794, PMID 32860331, PMID 34632876, PMID 34749008, PMID 35254001, PMID 35771552, PMID 36184621, PMID 39113428, PMID 40789106, PMID 41114938
U10CA021115 (2), U10CA180820 (2), P30CA016672 (1), P30CA022453 (1), R21CA153000 (1), U24CA196172 (1), UG1CA189867 (1)